Pregabalin Capsule
Product Images NDC 43598-294

Product Visual Gallery

This gallery contains 29 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 43598-294). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. Four curves represent different treatment groups: pregabalin 200 mg three times a day, pregabalin 100 mg three times a day, pregabalin 25 mg three times a day, and placebo. The graph illustrates comparative patient improvement among these groups.*

FDA Label Image

Figure2 (Figure2)

A line graph depicting the percent improvement in pain from baseline on the X-axis versus the percent of patients improved on the Y-axis. Two lines compare pregabalin 100 mg taken three times a day and placebo, showing higher patient improvement with pregabalin across pain improvement percentages.*

FDA Label Image

Figure3 (Figure3)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. It compares four groups: pregabalin 300 mg twice a day, pregabalin 150 mg twice a day, pregabalin 75 mg twice a day, and placebo. The graph shows the response distribution across these treatments.*

FDA Label Image

Figure4 (Figure4)

A line graph comparing percent improvement in pain from baseline versus percent of patients improved. It shows three lines representing pregabalin 200 mg three times a day, pregabalin 100 mg three times a day, and placebo. The x-axis is percent improvement in pain from baseline, and the y-axis is percent of patients improved.*

FDA Label Image

Figure5 (Figure5)

A line graph depicting percent improvement in pain from baseline versus percent of patients improved. It compares pregabalin 100 mg three times a day, pregabalin 50 mg three times a day, and placebo groups, showing the relationship between pain improvement percentages and patient response rates.*

FDA Label Image

Figure6 (Figure6)

A bar chart presenting responder rates (%) from two studies, E1 and E3, comparing placebo with various doses of pregabalin ranging from 50 mg/day to 600 mg/day. The chart illustrates increasing responder rates with higher doses across both studies, with numerical responder percentages displayed above each bar and sample sizes listed below.*

FDA Label Image

Figure7 (Figure7)

A dose-response line graph depicting seizure reduction as median percentage change from baseline with different doses of a drug measured in mg/day. Four study groups (E1 BD, E2 TID, E3 BD, E3 TID) are represented with distinct markers; the graph shows increasing seizure reduction with higher doses and significant p-values at multiple dose points.*

FDA Label Image

Carton1 (Carton1)

Pregabalin Capsules 25 mg unit dose carton for institutional use, labeled by Dr. Reddy's Laboratories Inc. The packaging contains 50 capsules (5 blister cards of 10 capsules each). The label warns the package is not child-resistant and advises to keep out of reach of children. Storage instructions and distributor information are also provided on the carton.*

FDA Label Image

Carton2 (Carton2)

Pregabalin Capsules, 50 mg oral dosage form in a unit dose package. The labeling states it is for institutional use only and contains 50 capsules (5 blister cards of 10 capsules each). The label references Dr. Reddy's Laboratories Inc as the distributor, includes the NDC 43598-292-66, and warns that the package is not child-resistant as well as to keep drugs out of children's reach.*

FDA Label Image

Carton3 (Carton3)

Box packaging label for Pregabalin Capsules, 75 mg, oral dosage form by Dr. Reddy's Laboratories Inc. The label indicates it is for institutional use only, contains 50 capsules in unit-dose packaging (5 blister cards of 10 capsules each), and notes the package is not child resistant. The NDC number 43598-293-66 is visible along with storage instructions and distributor information.*

FDA Label Image

Carton4 (Carton4)

Box label for Pregabalin Capsules 100 mg, oral capsules distributed by Dr. Reddy's Laboratories Inc. The label indicates the product is for institutional use only and contains 50 capsules (5 blister cards of 10 unit doses each). It includes storage instructions, dosage warnings, NDC 43598-294-66, and states the package is not child resistant.*

FDA Label Image

Carton5 (Carton5)

Packaging label for Pregabalin Capsules 150 mg by Dr. Reddy's Laboratories Inc. The label indicates a unit dose package of 50 capsules (5 blister cards of 10 capsules each) for institutional use only. It includes storage instructions and child safety warnings, along with the NDC 43598-295-66 and manufacturing details noting the product is made in India.*

FDA Label Image

Carton6 (Carton6)

Pregabalin Capsules, 200 mg, oral dosage form in a unit dose package containing 50 capsules (5x10 unit-dose). Label states it is for institutional use only, is not child resistant, and includes handling instructions. Manufactured by Dr. Reddys Laboratories Inc. The label includes the NDC 43598-296-66 and a barcode.*

FDA Label Image

Carton7 (Carton7)

Packaging label for Pregabalin Capsules 225 mg oral unit dose by Dr.Reddys Laboratories Inc. The carton contains 50 capsules packaged as 5 blister cards with 10 unit doses each. It states that the package is not child resistant and is for institutional use only.*

FDA Label Image

Carton8 (Carton8)

Packaging label for Pregabalin Capsules 300 mg by Dr. Reddys Laboratories Inc. This label is for a unit dose package containing 50 capsules (5 strips of 10 capsules). It includes usage warnings, storage instructions, NDC 43598-298-66, distributor information, and a barcode. The label is marked for institutional use only and notes that the unit dose package is not child resistant.*

FDA Label Image

Container1 (Container1)

Label for Pregabalin Capsules 25 mg by Dr. Reddys Laboratories Inc. The label states the strength as 25 mg per capsule and indicates that the package contains 90 capsules. It includes handling instructions, storage conditions, and a barcode. The label also displays the NDC number 43598-291-90 and the phrase Rx Only.*

FDA Label Image

Container2 (Container2)

Label for pregabalin capsules 50 mg by Dr.Reddy's Laboratories Inc. The label shows the drug name and strength, states 'Rx Only,' and includes directions for pharmacists to dispense the accompanying Medication Guide. It specifies that each capsule contains 50 mg pregabalin and provides storage instructions. The label also includes the NDC number 43598-292-90, barcode, distributor information, and packaging of 90 capsules.*

FDA Label Image

Container3 (Container3)

Pregabalin Capsules, 75 mg oral capsules labeled for prescription use. The label indicates a package size of 90 capsules. It includes dispensing instructions for pharmacists and storage conditions. The product is manufactured and distributed by Dr. Reddy's Laboratories Inc., made in India. The label also shows the NDC 43598-293-90 and barcode.*

FDA Label Image

Container4 (Container4)

Label for pregabalin Capsules, 100 mg, prescription oral capsules from Dr. Reddy's Laboratories Inc. The label states each capsule contains 100 mg of pregabalin USP and instructs pharmacists to dispense the accompanying Medication Guide. The package contains 90 capsules. Additional labeling includes storage instructions and a barcode.*

FDA Label Image

Container5 (Container5)

Label for Pregabalin Capsules 150 mg in a bottle containing 90 capsules. The label indicates prescription use only and includes dispensing instructions for pharmacists. The product is manufactured by Dr. Reddy's Laboratories Inc., made in India, with storage instructions and a barcode displayed.*

FDA Label Image

Container6 (Container6)

Label for Pregabalin Capsules 200 mg, oral dosage form, in a 90-count package by Dr. Reddys Laboratories Inc. The label includes dosage information, storage instructions, and a barcode. It highlights that each capsule contains 200 mg of pregabalin and is for prescription use only.*

FDA Label Image

Container7 (Container7)

Label for Pregabalin Capsules, 225 mg, oral dosage form. The label specifies prescription-only use and instructs pharmacists to dispense the accompanying medication guide. Each capsule contains 225 mg of pregabalin. The label includes storage instructions (20 to 25°C), child-resistant container requirement, and is manufactured by Dr. Reddy's Laboratories Inc., Princeton, NJ. The packaging contains 90 capsules and features a barcode and NDC 43598-297-90.*

FDA Label Image

Container8 (Container8)

Label for Pregabalin Capsules 300 mg by Dr.Reddys Laboratories Inc. The label indicates the capsule strength as 300 mg and states one capsule contains pregabalin USP. It mentions prescription-only use with a note for pharmacists to dispense the Medication Guide. The package size is 90 capsules. Storage instructions specify 20° to 25°C (68° to 77°F) controlled room temperature and to dispense in tight, child-resistant containers. The label includes a barcode, distributor address, and notes the product is made in India.*

FDA Label Image

Figure10 (Figure10)

A Kaplan-Meier survival curve graph showing the estimated percentage of subjects without LTR (loss to response) over 180 days. The graph compares the outcomes for two groups: one treated with Pregabalin and the other with a placebo, with time in days on the x-axis and the estimated percentage of subjects without LTR on the y-axis.*

FDA Label Image

Figure11 (Figure11)

A line chart compares the percent of subjects improved over time from baseline to Week 12 using the Brief Overall Change in Fibromyalgia (BOCF) measure. It plots two groups: pregabalin (solid line) and placebo (dashed line), showing higher improvement percentages for pregabalin across the time points.*

FDA Label Image

Figure12 (Figure12)

A line graph comparing the percent of subjects improved over time from baseline to Week 16 using the BOCF method for pregabalin versus placebo. The horizontal axis shows percent improvement, and the vertical axis shows the percent of subjects improved. Two trend lines represent pregabalin and placebo outcomes, illustrating higher improvement rates for pregabalin throughout the range.*

FDA Label Image

Figure9 (Figure9)

A line chart comparing the percent of patients improved against the percent improvement in pain from baseline for pregabalin at daily doses of 300 mg, 450 mg, and 600 mg, and a placebo. The y-axis shows the percent of patients improved, ranging from 0 to 100%, and the x-axis shows percent improvement in pain from baseline, ranging from 0 to 100%. Different line styles represent each dose and placebo.*

FDA Label Image

Structure1 (Structure1)

A formula for calculating creatinine clearance (CLCr), showing the use of age in years, weight in kilograms, serum creatinine in mg/dL, and a correction factor of 0.85 for female patients.*

FDA Label Image

Structure2 (Structure2)

Chemical structure of pregabalin, showing its molecular framework including an amino group, carboxyl group, and branching hydrocarbon chain, consistent with the active ingredient pregabalin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.